Rakuten Medical

The Alluminox platform is an investigational treatment platform based on photoimmunotherapy, a cancer therapy.

Rakuten Medical develops products with the goal of obtaining regulatory approval.

Rakuten Medical is developing Alluminox platform-based photoimmunotherapy for patients around the world.

The EMA opened an office in Amsterdam in March 2019.

Rakuten provided $100 million in series C1 financing for Rakuten Medical.

Rakuten Medical, Inc. is a clinical-stage global biotechnology company developing precision-targeted cancer therapies.

2018 Milestones

Rakuten Medical, Inc. develops investigational, cell-targeting therapies on its Alluminox technology platform.

News - Rakuten Medical - To conquer cancer.

The company provides a press kit for media members.

Rakuten Medical, Inc. develops and commercializes Alluminox platform-based photoimmunotherapy.

As COO, Abhijit Bhatia oversees Global Corporate Finance & Accounting and Global Corporate & Business Development.

Rakuten Medical CEO Minami is advancing a new treatment modality.

Q4 2013 to Q1 2015 Milestones

2015 Milestones

2016 Milestones

Rakuten Medical, Inc. develops and commercializes precision, cell-targeting photoimmunotherapy based on its Alluminox platform.

BD and Partnerships - Rakuten Medical - To conquer cancer.

Rakuten Medical provides an inquiry form and email contact.

Medical Information - Rakuten Medical - To conquer cancer.

Other - Rakuten Medical - To conquer cancer.

Rakuten Medical, Inc. develops precision, cell-targeting investigational therapies on its Alluminox technology platform. Preclinical studies have shown the therapies induce rapid, selective cell killing and tumor necrosis.

The privacy policy, effective May 17, 2019, describes the practices of Rakuten Medical, Inc. and its subsidiaries.